Lexeo’s gene therapy for rare heart disease shows promise in trial

Lexeo Therapeutics stated Monday {that a} gene remedy designed to stop deadly cardiac issues of a genetic dysfunction known as Friedrich’s ataxia lowered indicators of coronary heart illness in a handful of sufferers.

The information are very early and less-than-clear-cut. However given a high Meals and Drug Administration official’s current efforts to advance gene therapies underneath accelerated approval — most notably, with the choice to broaden approval for Sarepta’s Duchenne muscular dystrophy therapy, regardless of two failed trials— the corporate thinks it could possibly chart a path to market, after an extra examine.

“In my view, it sits squarely in the kind of framework that Peter Marks has been type of driving,” stated Lexeo CEO Nolan Townsend, referring to the director of the company’s biologics division.